Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2021-04-12 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is very short (910 characters) and contains a confirmation certificate related to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It is addressed to the Compliance Officer/Company Secretary of Lyka Labs Limited. There is no substantive financial data, no detailed report, or financial statements. The content is a regulatory compliance certificate rather than a full report or announcement of financial results. According to the Certification Rule, such officer certifications or confirmations should be classified as Regulatory Filings (RNS).
2021-04-12 English
Pursuant to Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Compliance Certificate, duly signed by Authorized Signatory ....
Regulatory Filings
2021-04-12 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2021-04-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is extremely short (386 characters) and contains only header information related to stock exchanges and script codes, with no substantive content or financial data. There is no indication of a full report, announcement, or detailed filing. Given the brevity and lack of content, this is likely a regulatory announcement or a placeholder document without detailed information. According to the rules, such short documents that do not contain actual report content or detailed announcements fall under Regulatory Filings (RNS).
2021-03-31 English
This is to inform you that pursuant to the NSE circular no. NSE/CML/2019/11 and BSE circular no. LIST/COMP/01/2019-20 read with clause 4 of Schedule B of the SEBI (Prohibition of SEBI Insider ....
Regulatory Filings
2021-03-31 English
1. Considered and Approved Un-audited Standalone Financial results for the Third Quarter ended 31st December, 2020; 2. Considered and Approved Un-audited Consolidated Financial results ....
Regulatory Filings
2021-02-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.